Summary
Gilead Sciences, Inc. (GILD) announced a key leadership change in its finance department through an 8-K filing on October 15, 2019. Andrew Dickinson has been appointed as the new Chief Financial Officer (CFO), effective November 1, 2019. This transition follows the retirement of Robin Washington, who will remain in an advisory role until the conclusion of the company's 2019 financial reporting. Dickinson's appointment signals a strategic move within Gilead's executive team, bringing in a leader with significant experience in corporate development, strategy, and healthcare investment banking. Dickinson's compensation package includes a base salary of $950,000, a 100% target annual bonus, and significant equity awards for 2020 valued at $3.5 million. He also received an initial grant of $1 million in restricted stock units and stock options upon his appointment. This filing also includes a press release and a letter outlining the terms of Dickinson's engagement, providing investors with transparency into the financial and leadership structure of the company.
Key Highlights
- 1Andrew Dickinson appointed as Chief Financial Officer (CFO), effective November 1, 2019.
- 2Current CFO, Robin Washington, to retire but will remain in an advisory capacity through the end of 2019.
- 3Dickinson brings extensive experience in corporate development, strategy, and healthcare investment banking, having joined Gilead in 2016.
- 4Dickinson's new role comes with an annual base salary of $950,000 and a 100% target annual bonus opportunity.
- 5For 2020, Dickinson is set to receive annual equity awards with a target value of $3,500,000.
- 6Upon appointment, Dickinson received initial equity awards valued at $1,000,000, split between RSUs and stock options.
- 7The filing includes a press release and the letter of engagement for Andrew Dickinson.